Diagnosis, Prognosis and Management of Hematologic Malignancies

Dear Colleagues,

Hematologic malignancies are cancers affecting blood, bone marrow and lymphonodes. They include leukemias, myeloproliferative and lymphoproliferative neoplasms, including polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF), lymphoma and multiple myeloma (MM), respectively. Acute myeloid leukemia (AML) is a clonal hematopoietic disorder characterized by a block in myeloid differentiation. Despite an improved understanding of the molecular and phenotypic characteristics of AML, there is a poor or moderate anti-leukemic response or relapse following short remission. Therefore, the identification of therapeutic targets expressed on leukemia stem cells might improve the potential clinical of AML treatment as well as predict patient outcome. Myeloproliferative neoplasms (MPNs) are malignancies caused by somatic driver mutations, such as JAK2V617F. MPNs have critical outcomes, including progression to MF or blast phase disease (MPN-BP), thrombosis and death. As a result, novel approaches are needed to understand and predict outcomes in MPN patients. MM arises from malignant plasma cells. Despite the introduction of novel therapeutic agents, MM remains an incurable disease with frequent relapses. Therefore, the identification of the mechanisms by which tumor cells evade therapy is warranted. Diffuse large B-cell lymphoma (DLBCL) is a lymphoid cancer characterized by frequent relapses. Therefore, studies on the pathogenesis of DLBCL are recommended.

Prof. Dr. Rossella Cacciola
Dr. Emma C. Cacciola
Dr. Alessandra Romano
Dr. Alessandro Allegra
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• leukemia
• myeloproliferative neoplasms
• myeloma
• lymphoma